Goldstein Advisors LLC Has $530,000 Stock Holdings in Exact Sciences Corporation (NASDAQ:EXAS)

Goldstein Advisors LLC increased its position in shares of Exact Sciences Corporation (NASDAQ:EXAS - Free Report) by 113.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,254 shares of the medical research company's stock after acquiring an additional 6,523 shares during the period. Goldstein Advisors LLC's holdings in Exact Sciences were worth $530,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Robeco Institutional Asset Management B.V. boosted its position in shares of Exact Sciences by 298.6% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 148,629 shares of the medical research company's stock worth $6,434,000 after acquiring an additional 111,343 shares in the last quarter. Global Assets Advisory LLC acquired a new stake in Exact Sciences in the first quarter valued at approximately $280,000. FORM Wealth Advisors LLC acquired a new stake in Exact Sciences in the first quarter valued at approximately $342,000. Asset Management One Co. Ltd. boosted its position in Exact Sciences by 4.5% in the first quarter. Asset Management One Co. Ltd. now owns 68,500 shares of the medical research company's stock valued at $2,965,000 after buying an additional 2,949 shares in the last quarter. Finally, Walkner Condon Financial Advisors LLC boosted its position in Exact Sciences by 10.7% in the first quarter. Walkner Condon Financial Advisors LLC now owns 9,430 shares of the medical research company's stock valued at $418,000 after buying an additional 913 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.

Exact Sciences Trading Up 3.6%

NASDAQ EXAS traded up $1.84 during mid-day trading on Friday, reaching $53.65. 9,017,373 shares of the stock were exchanged, compared to its average volume of 2,571,371. Exact Sciences Corporation has a one year low of $39.97 and a one year high of $72.83. The stock has a 50 day simple moving average of $52.83 and a 200-day simple moving average of $51.35. The stock has a market cap of $10.12 billion, a P/E ratio of -9.74, a P/E/G ratio of 40.73 and a beta of 0.98. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.73 and a quick ratio of 2.38.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.16. Exact Sciences had a negative net margin of 36.06% and a negative return on equity of 3.75%. The business had revenue of $706.79 million during the quarter, compared to the consensus estimate of $688.58 million. During the same quarter last year, the firm earned ($0.60) earnings per share. Exact Sciences's quarterly revenue was up 10.9% on a year-over-year basis. On average, analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on EXAS. Evercore ISI raised their target price on shares of Exact Sciences from $60.00 to $66.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Royal Bank Of Canada raised their target price on shares of Exact Sciences from $52.00 to $54.00 and gave the company a "sector perform" rating in a research report on Friday, May 2nd. Robert W. Baird raised their target price on shares of Exact Sciences from $69.00 to $72.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Mizuho began coverage on shares of Exact Sciences in a research report on Thursday, April 10th. They issued an "outperform" rating and a $60.00 target price on the stock. Finally, Guggenheim restated a "buy" rating and issued a $60.00 target price on shares of Exact Sciences in a research report on Friday, April 11th. Two equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $70.40.

Insider Buying and Selling

In other Exact Sciences news, Director Katherine S. Zanotti sold 3,207 shares of the firm's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $53.20, for a total value of $170,612.40. Following the completion of the sale, the director now directly owns 72,759 shares in the company, valued at approximately $3,870,778.80. This trade represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is owned by insiders.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.